5 articles in this category
For teams designing antibody-drug conjugates (ADCs) or other targeted therapeutic conjugates, the linker is rarely the star of the show. The payload g...
Cell therapies are not pills. They expand, contract, migrate, and exhaust. Their pharmacokinetics (PK) and pharmacodynamics (PD) follow rules that loo...
Introduction: The Next Frontier in Biologic DesignBiologic therapies have revolutionized medicine, yet many still fall short of their full potential d...
The New Imperative: From Bulk Batches to Bespoke VialsFor decades, biopharma supply chains were engineered for predictability: massive, stable batches...
Half-life is the first number everyone asks for in biologic development. But it is also one of the most misleading. A 21-day half-life sounds reassuri...